CHEMICAL AND BIOLOGICAL PROFILING OF WEEDS AND MEDICINAL PLANTS TARGETING PROTEIN KINASE AND PHOSPHATASES IN SIGNAL TRANSDUCTION IN CANCER



THESIS SUBMITTED IN FULFILLMENT FOR THE DEGREE OF MASTER OF PHILOSOPHY

SCHOOL OF SCIENCE AND TECHNOLOGY UNIVERSITI MALAYSIA SABAH 2013

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, excerpts, equation summaries and references which have been duly acknowledged.

07 September 2012

Azlinah Binti Matawali PS2008-8418



CERTIFICATION

NAME : **AZLINAH BINTI MATAWALI**

MATRIC NO. : **PS2008-8418**

TITLE : CHEMICAL AND BIOLOGICAL PROFILING OF BIOACTIVE

WEEDS AND MEDICINAL PLANTS TARGETING PROTEIN KINASE AND PHOSPHATASES IN SIGNAL

TRANSDUCTION IN CANCER.

DEGREE : MASTER OF PHILOSOPHY (BIOTECHNOLOGY)

VIVA DATE : 26 NOVEMBER 2012

DECLARED BY

1. SUPERVISOR

Assoc. Prof. Dr. Jualang Azlan Gansau

Signature

UNIVERSITI MALAYSIA SABAH

2. CO-SUPERVISOR 1

Assoc. Prof. Dr. Lee Ping Chin

3. CO-SUPERVISOR 2

Assoc. Prof. Dr. How Siew Eng

ABSTRACT

CHEMICAL AND BIOLOGICAL PROFILING OF WEEDS AND MEDICINAL PLANTS TARGETING PROTEIN KINASE AND PHOSPHATASES IN SIGNAL TRANSDUCTION IN CANCER

A total of 162 methanolic extracts of plant collected from Sabah were studied and screened for novel bioactive compounds against protein kinase and phosphatases involved in signal transduction in cancer. The targeted protein screening systems were kinase (MKK1) and phosphatase (MSG5 and PP1) which using different strain of mutated yeast namely MKK1^{P386}, MKK1^{P386}-MSG5, PAY704-1 and PAY700-4. Screening of crude methanolic extracts showed 13 potential extracts against PP1 protein which classified as inhibitor to GLC7 (UMS71, UMS91 and UMS990); inhibitor sensitive to glc7-10 catalytic domain change (UMS80) and inhibitor insensitive to glc7-10 catalytic domain change (UMS70, UMS108, UMS901, UMS908, UMS963, UMS974, UMS975, UMS984 and UMS993). Meanwhile, about 21 and 26 crude methanolic extracts including UMS643 were found as toxic against MKK1 and MSG5 screening assay, respectively. Four extracts (UMS71, UMS91, UMS108 and UMS643) had been selected to further separate by using liquid-liquid extraction methods and subsequently re-tested against all screening assay. However, only UMS71 and UMS91 showed consistent inhibitions against PP1 screening assay. The potential extracts partitions are Chloroform (CE), Hexane (HE) and Ethyl acetate (EAE) from UMS71 and Chloroform (CE) from UMS91. They were found to be inhibitor insensitive to qlc7-10 catalytic domain change with the inhibitory zones ranged between 7.33±1.15mm until 9.5±0.70mm. Thus, both UMS71 (Chromoleana odorata) and UMS91 (Mikania micrantha) had been chromatographed through Thin Layer Chromatography (TLC) and Column Chromatography. Each column fraction was screened against PP1 screening assay and the results showed 8 potential fractions from CE of UMS71. Fraction 2 (F2) was classified as inhibitor to GLC7 and exhibited strongest inhibitory zones ranged between 8.00±0.00mm until 15.0±0.0mm. As for UMS91, Fraction 2 (F2) of CE also showed activities during PP1 screening assay. This fraction was classified as inhibitor to GLC-7 with the range between 13.5±0.7mm until 14.0±1.4mm. Phytochemical test had been conducted on UMS71 dan UMS91 extracts whereas both UMS71.CE (Fraction F1-F10) and UMS91.CE (Fraction F1-F5) were scanned through UV/Vis spectroscopy. The presence of alkaloid, flavonoid, tannin, saponin and triterpenoid were observed on both samples. However, only selected fraction (UMS71.CE.F2) possessed the consistent which most antiphosphatase activities had been analysed for compounds identification by using GC-MS. The analysis revealed the presence of 10 compounds. The dominant phytocomponents in the extract fraction are hexachloro-ethane, n-nonylaldehyde, methyl-4-oxooctanoate, longiverbenone, 2-butenal, 2-methyl-4-(2,6,6-trimethyl-1cyclohexen-1-yl), neophytadiene, phytol, dihydro-neoclovene, aromadendrene and 2,6-ditert-butylquinone. Fraction UMS71.CE.F2 had also chosen to undergo the enzymatic analysis in order to determine the specificity of inhibitions against protein phosphatase type-1 (PP1). Spectrophotometric method was used to assay for the enzyme activity and both maximum enzyme velocity (V_{max}) and Michealis-Menten (K_m) constants were evaluated and compared for normal and inhibited reactions. The K_m and V_m for substrate (DiFMUP) were 0.125mM and 125 while the $K_{m'}$ and $V_{m'}$ at 300 μ g/ μ l were 0.60mM and 200.0, respectively. Other biological activities such as in-vitro cytotoxicity and antimicrobial test of UMS71 also had been reported. However, cytotoxicity test was only conducted at CE partitions level were found to exhibits cytotoxic activities against HeLa cervix adenocarcinoma (IC₅₀ value 39.00±1.00µg/ml) cancer cell lines. Meanwhile, antibacterial test carried out for UMS71.CE.F2 showed week inhibitory activities on S. pneumonia (11.67±2.08mm), S. aureus (10.33±0.58mm), P. aeruginosa (10.67±0.58mm), E. coli (8.00±0.00mm) and S. typhii (8.00±0.00mm) when compared to ampicillin as control positive.

Keyword: Kinase, Phosphatases, Signal transduction, Cancer, Chromolaena odorata



ABSTRAK

Sebanyak 162 ekstrak metanol daripada tumbuhan yang didapati dari Sabah telah dikaji bagi menentukan kehadiran sebatian bioaktif terhadap protein kinase dan fosfatase yang lazimnya terlibat dalam transduksi isyarat pada mekanisme kanser. Ujian penyaringan ini memfokuskan kepada perencat kinase (MKK1) dan perencat fosfatase (MSG5 dan PP1) menggunakan strain yis yang telah dimutankan iaitu MKK1^{P386}, MKK1^{P386}-MSG5, PAY704-1 dan PAY700-4. Penyaringan ekstrak metanol kasar menunjukkan sebanyak 13 ekstrak telah merencatkan protein PP1 yang mana dapat dikelaskan kepada kumpulan perencat terhadap GLC7 (UMS71, UMS91 dan UMS990); perencat sensitif kepada perubahan domain katalisis qlc7-10 (UMS80) dan perencat tak sensitif kepada perubahan domain katalisis glc7-10 (UMS70, UMS108, UMS901, UMS908, UMS963, UMS974, UMS975, UMS984 dan UMS993). Sebanyak 21 ekstrak metanol kasar didapati bersifat toksik kepada protein MKK1, manakala 26 ekstrak pula didapati toksik kepada protein MSG5 termasuklah UMS643 yang menunjukkan sifat toksik kepada kedua-dua protein tersebut. Oleh yang demikian, empat ekstrak kasar (UMS71, UMS91, UMS108 and UMS643) telah dipilih untuk pemisahan menggunakan teknik pemisahan cecaircecair. Ujian penyaringan semula bagi semua pecahan ekstrak menunjukkan hanya UMS71 dan UMS91 sahaja memberikan perencatan yang konsisten terhadap ujian PP1; iaitu pada pecahan ekstrak daripada klorofom (CE), heksana (HE) dan etil asetat (EAE) daripada ekstrak UMS71 serta pecahan klorofom (CE) daripada ekstrak UMS91. Pecahan-pecahan ini merupakan perencat tak sensitif kepada perubahan domain katalisis glc7-10 dengan julat zon perencatan sebanyak 7.33±1.15mm sehingga 9.5±0.70mm. Sehubungan itu, ekstrak (Chromoleana odorata) dan UMS91 (Mikania micrantha) telah dikromatografikan menggunakan teknik Kromatografi Lapisan Nipis (TLC) dan Kromatrografi Turus. Setiap fraksi yang terhasil telah diuji semula terhadap ujian penyaringan PP1. Terdapat 8 fraksi yang berpotensi pada CE ekstrak UMS71 telah dikenalpasti termasuklah fraksi 2 (F2) yang merupakan perencat terhadap GLC7. Fraksi ini mencatatkan zon perencatan yang paling besar iaitu pada julat 8.00±0.00mm sehingga 15.0±0.0mm. Bagi ekstrak UMS91, hanya fraksi 2 (F2) pada CE ekstrak yang bersifat perencat terhadap GLC7 dengan julat perencatan sebanyak 13.5±0.7mm sehingga 14.0±1.4mm. Ujian fitokimia telah dilakukan ke atas semua ekstrak daripada UMS71 dan UMS91 manakala pecahan ekstrak UMS71.CE (Fraksi F1-F10) dan UMS91.CE (Fraksi F1-F5) telah diimbas menggunakan spektroskopi UV/Vis. Ujian fitokimia mengesahkan kehadiran alkaloid, flavonoid, tannin, saponin dan triterpenoid pada kedua-dua sampel tersebut. Walaubagaimanapun, hanya fraksi terpilih (UMS71.CE.F2) telah dianalisis menggunakan GC-MS. Hal ini kerana fraksi ini mempunyai kadar perencatan antifosfatase yang lebih konsisten dan bersaiz besar berbanding ekstrak lain. Data menunjukkan kehadiran 10 jenis sebatian pada pecahan ekstrak tersebut iaitu hexachloro-ethane, n-nonylaldehyde, methyl-4-oxooctanoate, longiverbenone, 2-butenal,2-methyl-4-(2,6,6-trimethyl-1-

cyclohexen-1-yl), neophytadiene, phytol, dihydro-neoclovene, aromadendrene dan 2,6-ditert-butylquinone. Di samping itu, fraksi UMS71.CE.F2 juga telah diuji pada ujian analisa enzim bagi mengesahkan kespesifikasiannya terhadap protein fosfatase jenis-1 (PP1). Kaedah spektrofotometrik dilakukan untuk menentukan nilai maksimum kealiran enzim (V_{max}) dan pemalar Michealis-Menten (K_m) sama ada dengan kehadiran perencat atau sebaliknya. Nilai K_m dan *V_m* bagi substrat (DiFMUP) pada reaksi normal adalah masing-masing sebanyak 0.125mM and 125, manakala nilai $K_{m'}$ and $V_{m'}$ pada kepekatan 300ug/ul adalah sebanyak 0.60mM and 200.0. Aktiviti biologi lain seperti ujian sitotoksik secara in-vitro dan ujian antimikrobial juga telah dilaporkan pada sampel UMS71. Ujian sitotoksik yang hanya dilakukan menggunakan pecahan ekstrak CE menunjukkan aktiviti ketoksikan pada sel kanser HeLa cervix adenocarcinoma (nilai IC50 39.00±1.00µg/ml). Ujian antibakteria pada fraksi UMS71.CE.F2 pula telah menunjukkan perencatan lemah terhadap S. pneumonia (11.67±2.08mm), aureus (10.33±0.58mm). aeruginosa (10.67±0.58mm), Р. (8.00±0.00mm) and S. typhii (8.00±0.00mm) berbanding ampicillin yang bertindak sebagai kawalan positif.

Kekunci : Kinase, Fosfatase, Transduksi isyarat, Kanser, Chromolaena odorata

UNIVERSITI MALAYSIA SABAH

ACKNOWLEDGEMENT

In the name of Allah, the Most Gracious and the Most Merciful.

All praises to Allah for the strengths and His blessing. The completion of this thesis was made possible through the invaluable contribution of a number of individual. Foremost, my utmost gratitude to my supervisor Assoc. Prof. Dr. Jualang Azlan Gansau for his patience and guidance during the research and writing of this thesis. I would also like to thank my thesis committee; Assoc. Prof. Dr. Lee Ping Chin and Assoc. Prof. Dr. How Siew Eng for their encouragement and insightful comments.

I would like to express my appreciation to MOSTI for the scholarship, our collaborators Dr. Latifah Saiful Yazan (UPM), Mr. Didi Erwandi Mohd Haron (UM), Mr. Julius Kulip and Mr. Johnny Gisil (IBTP, UMS) and also staffs of Klias Peat Swamp Forest, Klias, Sabah. I expand my thanks to all lecturers and staffs from Biotechnology programme especially Assoc. Prof. Dr. Zaleha Abd Aziz for their constant moral supports and encouragement.

I am indebted to my fellow labmates; Ainil Farhan, Nurul Ain and Jury Tise Taunson for the sleepless nights we were working together. I also owe my gratitude to numerous undergraduates that had been helping me completing this research. Thanks for helping me get through the difficult times and for all the emotional support, comraderie, sincere encouragement and inspiration for these past few years.

Sincere thanks also to my colleagues especially Makdi, Noorhanis, Norhaniza, Ozayanna, Bong, Gabriella, Adznila, Fauze and Fitri Rozlianah for their kindness during my study. Words also fail me to express my appreciation to Fadzillah for always beside me during the happy and hard moments. Thanks for the friendship and memories.

My deepest gratitude also goes to my father, brothers and sister for their endless supports, unflagging love, prayers and encouragement. To those who indirectly contributed in this research, your kindness means a lot to me. Thank you.

Azlinah Matawali 7 September 2012

TABLE OF CONTENTS

TTT: C			Page
	ARATION IFICATION	1	ii iii
	OWLEDGE		iv
ABSTE	RACT		٧
ABSTI	RAK		vii
LIST (OF CONTE	NTS	ix
LIST (OF TABLES		χi
LIST (OF FIGURE	S	xiv
	OF PHOTO		XV
	OF SYMBO		xviii
	OF ABBRE		XİX
LIST (OF APPEND	DIX	XX
CHAP.	TER 1 :	INTRODUCTION	1
	TER 2 :	LITERATURE REVIEWS	
2.1	Cancer	and a second Acad Call Cine alling	4
2.2		velopment And Cell Signalling	5 9
2.3	Protein Kin 2.3.1	-00 AO	9
124	2.3.1	Mitogen activated protein kinase (MAPK) MAPK pathway in human and Saccharomyces cerevisiae	11
(-1	2.3.3	Kinase inhibitors	13
	2.3.4	MAPK (<i>MKK1</i>) inhibitor screening system	14
2.4	Protein Pho		15
	2.4.1	MAPK phocphatace	15
	2.4.2	Protein serine/threonine phosphatase	17
	2.4.3	Phosphatase inhibitors	19
	2.4.4	MAPK phosphatase (<i>MSG5</i>) inhibitor screening system	20
	2.4.5	Type-1 protein serine/threonine phosphatase (glc7) inhibitor screening system	21
2.5	Bioactive (Profiling	Compound(s) Isolation And Other Biological Activities	21
	2.5.1	Bioactive compound(s) isolation and purification	21
	2.5.2	Enzyme kinetic analysis	22
	2.5.3	Cytotoxicity assay	25
	2.5.4	Antimicrobial assay	26
2.6	Plant Phyto	•	27
	2.6.1	Plant secondary metabolites in drug discovery an development	27
2.7		Medicinal Plants	29
	2.7.1	Chromolaena odorata (L.) King and Robinson (UMS71)	30
	2.7.2	Mikania micrantha (H.B.K) (UMS91)	33
	2.7.3	Clidermia hirta (L.) D. Don (UMS108)	36

	2.7.4	Gleichenia linearis (Burm.) Underw. (UMS643)	38
CHAP	ΓER 3 :	SAMPLES COLLECTION, EXTRACTION AND SCREENING OF METHANOLIC CRUDE EXTRACTS AGAINST KINASES (MKK1) AND PHOSPHATASES (MSG5 AND PP1) INHIBITORS	
3.1	Introduction	•	40
3.2	Materials A	nd Methods	41
	3.2.1	Samples collection and preparation	41
	3.2.2	Samples crude extraction	42
	3.2.3	Yeast strains preparation and maintenance	42
	3.2.4	Screening of methanolic crude extracts against kinases	44
3.3	Doculto Ano	(MKK1) and phosphatases (MSG5and PP1) inhibitors. I Discussions	49
3.3	3.3.1	Samples collection, extraction and yeast strain	49
	3.3.1	preparation	73
	3.3.2	Inhibition of <i>MKK1</i> , <i>MSG5</i> and <i>Glc7</i> using methanolic	55
		crude extracts	
	3.3.3	Summary of selected samples	75
3.4	Conclusion		77
CHAD	ΓER 4 :	FRACTIONATION AND ISOLATION OF	
		BIOACTIVE COMPOUND(S) FROM SELECTED	
(EY		SAMPLES.	
4.1	Introduction	1 2	79
4.2	Materials A	nd Methods	80
	4.2.1	Fractionation and isolation of bioactive compound(s)	80
		from selected samples.	
	4.2.2	Profiling of bioactive compound(s) from selected	86
4.3	Doculto Ano	sample. I Discussions	89
4.3	4.3.1	Fractionation and isolation of bioactive compound(s)	89
	7.5.1	from selected samples.	03
	4.3.2	Profiling of bioactive compound(s) from selected	106
		sample.	
4.4	Conclusion	•	115
CHAP	ΓER 5 :	ENZYMATIC ASSAY FOR CHROMOLAENA ODORATA (L.f) KING AND ROBINSON AS PROTEIN PHOSPHATASE TYPE-1 (PP1)	
		INHIBITOR	
5.1	Introduction		117
5.2	Materials A		118
	5.2.1	Explants selection and extracts preparations	118
	5.2.2	Protein phosphatase 1 (PP1) enzyme and assay kit	118
	5.2.3 5.2.4	Assay for PP1 activity Assay for UMS71.CE.F2 activity	119 119
	5.2. 4 5.2.5	Assay of LIMS71.CE.F2 activity Assay of LIMS71 CF F2 as an inhibitor for PP1	110

5.3	Results A	nd Discussions	120
	5.3.1	Assay for PP1 activity	120
5.4	Conclusio	n	126
СНА	PTER 6:	CYTOTOXICITY AND ANTIMICROBIAL ACTIVITIES OF CHROMOLAENA ODORATA (L.f) KING AND ROBINSON	
6.1	Introduct	ion	127
6.2	Materials	and Methods	128
	6.2.1	Explants and extracts preparation	128
	6.2.2	In-vitro cytotoxicity activity of UMS71	129
	6.2.3	Bacterial strains preparation and maintenance	130
	6.2.4	Antimicrobial susceptibility testing (Disc diffusion assay)	130
6.3		nd Discussions	131
	6.3.1	In-vitro cytotoxicity activity of UMS71	131
<i>c</i> 1	6.3.2	Antimicrobial assay	132
6.4	Conclusio	on	136
СНА	PTER 7:	GENERAL DISCUSSIONS AND CONCLUSION	137
REFI	RENCES		145
APP	ENDIX I		159
APPI	ENDIX II		171
1			
	VA B	UNIVERSITI MALAYSIA SABAH	

LIST OF TABLES

		Page
Table 2.1	Mammalian MAPK phosphatases family.	17
Table 2.2	Major classes of plant chemicals.	28
Table 2.3	Details of <i>Chromolaena odorata</i> from the author's database.	31
Table 2.4	Classification of <i>Chromolaena odorata</i> .	31
Table 2.5	Details of <i>Mikania micrantha</i> from the author's database.	34
Table 2.6	Classification of <i>Mikania micrantha</i> .	34
Table 2.7	Details of <i>Clidermia hirta</i> from the author's database.	37
Table 2.8	Classification of <i>Clidermia hirta</i> .	37
Table 2.9	Details of <i>Gleichenia linearis</i> from the author's database.	39
Table 2.10	Classification of <i>Gleichenia linearis</i> .	39
Table 3.1	Genotype of yeast strains used in various type of screening assay.	43
Table 3.2	The expected results of the inhibitors upon PP1 screening assay.	48
Table 3.3	The list of plant samples collected around Sabah.	50
Table 3.4	Bioactivities of the sample extracts against MKK1	57
Table 3.5	screening assay. Bioactivities of the sample extracts against MSG5 screening assay.	63
Table 3.6	Bioactivities of the sample extracts against PP1 screening assay.	68
Table 3.7	Summary of the preliminary result of the UMS71, UMS91, UMS108 and UMS643.	75
Table 4.1	Organic solvents used for solvent system optimization by using thin layer chromatography (TLC).	84
Table 4.2	Bioactivities of the LLE fractions (UMS71, UMS91,	91

	UMS108 and UMS643) against MKK1 screening assay.	
Table 4.3	Bioactivities of the LLE fractions (UMS71, UMS91, UMS108 and UMS643) against MSG5 screening assay.	92
Table 4.4	Bioactivities of the LLE fractions (UMS71, UMS91, UMS108 and UMS643) against PP1 screening assay.	94
Table 4.5	Optimization profile of 1D-TLC for UMS71.HE, UMS71.EAE, UMS71.CE and UMS91.CE.	98
Table 4.6	Bioactivities of the CC Fractions (UMS71.CE and UMS91.CE) against PP1 screening assay.	105
Table 4.7	Major peaks recorded from UV spectral of UMS71.CE and UMS91.CE.	107
Table 4.8	Summary of phytochemicals constituents of UMS71 and UMS91.	109
Table 4.9	List of phytocomponents identified in UMS71.CE.F2.	111
Table 5.1	Comparisons of kinetic constants from both normal and inhibited reactions.	125
Table 6.1	In-vitro cytotoxicity activity (IC ₅₀ μg/ml ±SD) of UMS71.CE.	132
Table 6.2	Antibacterial activities of extracts obtained from <i>C. odorata</i> .	134

LIST OF ABBREVIATIONS

NCR National Cancer Registry

MAPK Mitogen Activated Protein Kinase

MAPKKMitogen Activated Protein Kinase KinaseMAPKKKMitogen Activated Protein Kinase Kinase

Kinase

MKK1 MAPK Kinase 1

MSG5multicopy supressor of gpa1ERKExtracellular regulated kinasep38Mammalian MAPK familyJNK1Mammalian MAPK familyp54α, p54β, p54γMammalian MAPK family

MKK1^{P386} hyperactive mutation form of MKK1

PP1 Protein phosphatase type 1PP2 Protein phosphatase type 2

MKB MAPK-binding

DSP dual-specificity phosphatase **ATP** Adenine Triphosphate **YPD** Yeast Peptone Dextrose

YPD+1M sorbitol Yeast Peptone Dextrose + 1 M Sorbitol PAY700-4 PP1 temperature sensitive yeast strain

PAY704-1
TLC
Thin Layer Chromatography
Gas chromatography
MS
MS
Wass Spectroscopy
U.S

MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl

tetrazolium bromide

Formazan 1-[4,5-dimethylthiazol-2-yl]-3,5-

diphenylformazan

C5 five carbon

IAW Invasive alien weed

C. odorata Chromolaena odorata (L.) King and Robinson

C. hirta Clidermia hirta (L.) D. Don

PBS Phosphate buffered saline solution

M. micrantha Mikania micrantha

ITBC Institute of Tropical Biology and Conservation

University Malaysia Sabah
BORH number
BORNEENSIS number

G. linearis Gleichenia linearis (Burm.) Underw

ES Enzyme-Substrate

U.S.A United States of America **DMF** N,N-dimethylformamide

DIFMUP 6,8-difluoro-4-methylumbelliferyl phosphate

ME Crude Methanolic Extract

HE Hexane Extract **EAE** EtnylAcetate Extract

CE Chloroform Extract

CME Chloroform: Methanol Extract

BEButhanol ExtractAEAqueous Extract3T3Normal cell line

HeLa Cervix adenocarcinoma

CaOV3 Ovarian cancer
A549 Lung cancer
Ext Excitation
Ems Emission



LIST OF SYMBOLS

 $\begin{array}{ll} K_m & \text{Michealis-Menten constant} \\ V_{max} & \text{Maximum observable velocity} \end{array}$

 $\begin{array}{lll} \beta & & \text{Beta} \\ \gamma & & \text{Gamma} \\ \alpha & & \text{Alpha} \end{array}$

°C Degree celcius

K₁ Rate constants for formation of ES

ES Enzyme-Substrate complex.

K₋₁ Rate constant of dissociation of ES

K_{cat}¹ Catalytic rate constant

R_t Reaction rate

[S]_t Instantaneous substrate concentration

mm milimitres
m metres
cm centimetres
% Percentage

(v/v) Volume per volume

< Less than
mg Miligram
ml Mililitre
- Negative
+ Addition

rpm Revolution per minutes

± Plus minus kDa Kilo Dalton U Unit

X Times

CO₂ Carbon dioxide

g Gravity µl Microlite

m/z Mass per charge ratio

UNIVERSITI MALAYSIA SABAH

LIST OF APPENDIX

		Page
Appendix I	Samples collection, extraction and screening of methanolic crude extracts against kinases (MKK1) and phosphatases (PP1 and MSG5) inhibitors.	160
Appendix II	Fractionation and purification of bioactive compound(s) from selected samples.	172



LIST OF FIGURES

		Page
Figure 2.1	Chemical structures of selected anti-cancer drugs that are in the clinic or in clinical trials.	5
Figure 2.2	Signaling pathways in normal cells. In cancer cells, however, mutations will lead to excessive proliferation that will cause stimulatory pathway (green) to continuously proliferate or inhibitory pathway (red) to lose its stop signal.	6
Figure 2.3	Three types of signaling modules and their response to agonist. Kinases and phosphatases involved in dual control switch of signaling mechanisms.	8
Figure 2.4	Mitogen-activated protein kinase (MAPK) signaling pathway. Mammalian MAPK family includes ERK, p38, and JNK.	10
Figure 2.5	MAPK pathway in human and <i>S. Cerevisiae</i> .	12
Figure 2.6	Chemical structures of drugs used as kinase inhibitors.	14
Figure 2.7	(a)Docking interaction between MAPK phosphatases (MKP) and MAP kinases (MAPK). (b) Activation of MKP by MAPK.	16
Figure 2.8	Examples of mechanisms involving PP1. Protein kinases and Protein Phosphatases regulate the activation of cyclin B-Cdc2.	19
Figure 2.9	Tautomycetin and Tautomycin as specific inhibitor of serine/threonine protein phosphatase type 1 (PP1).	20
Figure 2.10	Hyperbolic rate plot in a graph of R_t versus $[S]_t$.	23
Figure 2.11	Example of Lineweaver-Burke plot.	24
Figure 2.12	Chemical structure of MTT and its reduced formazan product.	26
Figure 3.1	The expected results of both MKK1 and MSG5 screening assay.	45
Figure 4.1	Slightly modified liquid-liquid separation techniques adapted from Harborne (1998).	82

Figure 4.2	GC chromatogram of UMS71.CE.F2 during GC-MS analysis.	112
Figure 4.3	Chemical structures of 10 predominant compounds of UMS71.CE.F2. Mass spectra of the isolated compounds from UMS71.CE.F2.	113
Figure 5.1	Chemical structures of DiFMUP and its product.	120
Figure 5.2	Reaction rates for normal reaction of PP1 and DiFMUP.	121
Figure 5.3	Lineweaver-Burke plot for normal reaction.	122
Figure 5.4	Rates of reaction of inhibitor were determined based on the time (min) versus relative fluorescence unit (RFU) graph.	123
Figure 5.5	A Lineweaver-Burke plot of 1/V (min/ μ g) vs 1/[DiFMUP] (mM $^{-1}$) at five fixed UMS71.CE.F2 concentrations.	124
Figure 6.1	Chemical structure of MTT and its reduced formazan product.	131

UNIVERSITI MALAYSIA SABAH

LIST OF PHOTO

		Page
Photo 2.1	Chromolaena odorata (L.) King and Robinson.	32
Photo 2.2	Mikania micrantha (H.B.K).	35
Photo 2.3	Clidermia hirta (L.) D. Don.	37
Photo 2.4	Gleichenia linearis (Burm.) Underw.	39
Photo 3.1	Toxic extracts (UMS108) of MKK1 screening assay. Partial inhibition zones were observed on glucose plate. Meanwhile, no yeast growth was detected on galactose media.	58
Photo 3.2	Toxic extracts (UMS904, UMS905 and UMS906) of MKK1 screening assay. On glucose plate, partial inhibition zones were observed on extract 906. However, more clear inhibitions were detected on both 904 and 905. No yeast growth was observed on galactose media.	59
Photo 3.3	Toxic extracts (UMS912, UMS915, UMS916 and UMS917) of MKK1 screening assay. Clear inhibitions zones were observed on all toxic extracts. However, no yeast growth on galactose media.	60
Photo 3.4	Toxic extracts (UMS108) of MSG5 screening assay. 108 found to exhibit faint inhibitory zones on both glucose and galactose plate.	64
Photo 3.5	Toxic extracts (UMS898, UMS903, UMS904, UMS905 and UMS906) of MSG5 screening assay. 904 and 905 showed highest inhibitory zones diameter on both glucose and galactose plate. Extracts 904 and 905 were exhibited clear inhibition zones on both glucose and galactose plate.	65
Photo 3.6	Potential extracts (UMS91) of PP1 screening assay. Clear inhibition zones were detected on yeast strain PAY704-1, YPD media at 37°C.	69

Photo 3.7	Clear inhibition zones of UMS91 were detected on yeast strain PAY700-4, YPD+1S media at 37°C. No yeast growth was detected on YPD media at 37°C.	70
Photo 3.8	Inhibitor to <i>GLC-7</i> (UMS71) in wild type yeast strain. Partial inhibition zones were detected at 37°C screening plate on both YPD and YPD+1S media.	71
Photo 3.9	Partial inhibition zones of UMS71 were detected on both YPD and YPD+1S media at 37°C.	72
Photo 3.10	Potential inhibitor that insensitive to glc7-10 catalytic domain change (UMS70 and UMS108). Both extracts exhibit inhibitory zones on yeast strain PAY704-1, YPD media at 37°C.	73
Photo 3.11	No significance activity showed when both UMS70 and UMS108 extracts screened against mutant yeast PAY700-4.	74
Photo 6.1	The inhibiton zones observed from UMS71.CE.F2 showed greater inhibitory zones than other extract. UNIVERSITEMALAYSIA SABAH	135

CHAPTER 1

INTRODUCTION

Cancer is the accumulation of mutations that causes dysregulation in cell functions. It is the leading cause of death worldwide and accounted for 13% of total deaths, which is equal to 7.6 million deaths in 2008 (World Health Organization, 2011). However, the numbers predicted to continue arise over 11 million in 2030. Five major cancers that recorded are lung, stomach, colorectal, liver and breast cancer (World Health Organization, 2011). In Malaysia, cancer is still one of the main health problems. National Cancer Registry (NCR) has reported 70 000 new cancer cases among Malaysians in Peninsular Malaysia between 2003 and 2005 (Lim *et al.*, 2008).

Signal transduction is a process of conveying signals from receptor upon reversible phosphorylation process that involves both kinases and phosphatases. Human genome has been reported to encode approximately 2000 protein kinases and 500 protein phosphatases (Cohen, 1999). Central building blocks in the intracellular signalling networks are the Mitogen-activated protein kinase (MAPK) pathway (Shaul and Seger, 2007). This pathway is activated by dual specificity MAPK kinases (MAPKKs) which are themselves activated by MAPKK kinases (MAPKKs) (Treisman, 1996). Regulation of the MAPKs activity is vital in signal transduction because it controls cellular processes. MAPKs itself have been linked with development and progression of several cancers; such as prostate cancer, breast, leukaemia and skin cancers (McCubrey *et al.*, 2007; Arnoidussen and Saatcioglu, 2009; Inamdar *et al.*, 2010). Hence, this pathway served as potential target in combating cancer diseases.

Previously, few kinase inhibitors were successfully introduced as cancer drugs such as Gleevac which had been approved for combating chronic myeloid leukemia (Noble *et al.*, 2004). Few others kinase inhibitors that currently available in market are such as m-amsacrine (m-AMSA), doxorubicin, vincristine (VCR) and choline phosphotransferase (CPT) (Yu, 1998). Meanwhile, numerous phosphatase inhibitors also had been continuously introduced as cancer drugs such as okadaic acid and tautomycetin (Shenolikar, 1994). However, some of these kinase and phosphatases inhibitors were found to encounter several issues such as drug-resistance problems, negative side effect issues, poor bioavailability and drug metabolism during early clinical trials and some drugs had problems in drug delivery. Thus, the searching for the new and novel anti kinase and phosphatase drug was urgently needed especially by manipulating the richness of our natural product sources.

Natural product offers broad spectrum of resources in drug discoveries. Approximately 23 new drugs derived from natural products that were used as treatments of various disorders since 2001 until 2005 (Lam, 2007). Plants have been widely used as therapeutic remedies. Plant-derived anticancer drugs have an impressive number in present clinical use and undergoing trials. However, competitions against new promising bioactive compounds derived from other natural sources such as terrestrial microbes and marine organisms forces the discovery of new and novel plant-derived anticancer agents. Challenges in overcoming the problems of drug target specificity, side effects and failure during clinical trials lead us to screen for new plant-derived novel inhibitors that effectively hit specific signal transduction involves in cancer.

Therefore, this study was conducted in order to search for the new plantderived kinase and phosphatase inhibitors found in Sabah. The objectives of this research are as follows;

- a) To collect, extract and screen the plant crude extracts against protein kinase (MKK1) and protein phosphatases (MSG5 and glc7).
- b) To fractionate and isoalate the bioactive compound(s) from selected samples against protein kinases or protein phosphatases.
- c) To conduct enzymatic analysis towards selected potential plant extracts and subsequently determine the value of kinetic constant (K_m and V_{max}).
- d) To study both *in vitro* cytotoxicity test and antimicrobial assay of the selected potential plant extracts.

